The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Management of adverse events from datopotamab deruxtecan in NSCLC
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the adverse events of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate (ADC), in patients with non-small cell lung cancer (NSCLC). Common side effects include mucositis, which can be managed with oral rinses and good mouthcare, as well as corneal adverse events, which can be treated with eyedrops. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
